Confidentiality Policy

Submitted abstracts are considered both CONFIDENTIAL and EMBARGOED from the time of submission.* For a study to be eligible for acceptance into an ASCO meeting, information contained in the abstract, as well as additional data and information to be presented about the study at the ASCO Meeting, must not be disclosed before the findings have been publicly released in conjunction with the ASCO Meeting. If information from the abstract or additional study are disclosed in advance of public release in conjunction with the ASCO Meeting, the abstract will no longer be eligible for inclusion in the ASCO Meeting, or will be subject to removal from the ASCO Meeting, unless an official Confidentiality Policy Exception applies.

The Confidentiality and Embargo Policies require that, prior to the embargo being lifted, the author, coauthors, and sponsor of the research not

1. make the information public, or provide it to others who may make it public (such as news media), 
    
2. publish or present the information or provide it to others who may publish or present it, or
    
3. use the information for trading in the securities of any issuer, or provide it to others who may use it for securities trading purposes. 

The First Author is responsible for conveying this information to all parties.

Furthermore, for a study to be eligible for acceptance into the ASCO Annual Meeting, the contents and conclusions of the abstract must not be presented at any scientific, medical, or educational meeting of 500 registrants or more or be published in a scientific, medical, or educational publication (in any medium), in whole or in part, before the ASCO Annual Meeting, either before or after submission to the Annual Meeting. ASCO-cosponsored meetings represent an exception to this restriction on prior presentation and publication.  Studies submitted to the Gastrointestinal Cancers Symposium, Genitourinary Cancers Symposium, Breast Cancer Symposium, Molecular Markers in Cancer Meeting, ASCO Quality Symposium, and other ASCO-cosponsored meetings where ASCO is the lead sponsor are eligible for acceptance even if previously presented or published in the scientific, medical, or educational arena. Abstracts presented at these particular ASCO meetings may also be submitted for presentation at any other ASCO meeting. For abstracts that have been previously presented at an ASCO-cosponsored meeting, authors are encouraged to provide updated data in the abstract, as the novelty of the data will be taken into account during the abstract selection process.

*The one exception to these policies applies to abstract information that has been previously made public through presentation at another meeting. In these cases, the confidentiality and embargo policies apply only to any updated information.